

\* \* \* \* \* STN Columbus \*  
\* \* \* \* \*

FILE 'HOME' ENTERED ON 23 NOV 1998

=> file uspatfull

=> s ((tumor? necros? factor?) or  
tnf?)(5a)receptor?

24416 TUMOR?  
7979 NECROS?  
432703 FACTOR?  
2469 TUMOR? NECROS? FACTOR?  
(TUMOR?(W)NECROS?(W)FACTOR?)  
2875 TNF?  
35182 RECEPTOR?  
L1 405 ((TUMOR? NECROS? FACTOR?) OR  
TNF?)(5A)RECEPTOR?

=> d 1-20

L1 ANSWER 1 OF 405 USPATFULL  
AN 1998:144233 USPATFULL  
TI Nucleic acids molecules encoding  
Caspase-8h and Caspase-8i  
IN Hunter, John J., Cambridge, MA, United  
States  
Shyjan, Andrew W., Nahant, MA, United  
States  
Wong, Grace H. W., Brookline, MA,  
United States  
PA Millennium Pharmaceuticals, Inc.,  
Cambridge, MA, United States  
(U.S. corporation)  
PI US 5837837 981117  
AI US 97-807200 970227 (8)  
DT Utility  
LN.CNT 2079  
INCL INCLM: 536/023.100  
INCLS: 530/300.000; 530/350.000  
NCL NCLM: 536/023.100  
NCLS: 530/300.000; 530/350.000  
IC [6]  
ICM: C07H021-02  
ICS: A61K038-00; C07K001-00  
EXF 536/23.1; 530/350; 435/172.3;  
435/69.1; 435/325; 424/93.2  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 2 OF 405 USPATFULL  
AN 1998:144213 USPATFULL  
TI **Tumor necrosis factor**  
**receptor-II-associated protein kinase**  
and methods for its  
use  
IN Aggarwal, Bharat B., Houston, TX,  
United States  
Darnay, Bryant G., Houston, TX, United  
States  
PA Research Development Foundation,  
Carson City, NV, United States  
(U.S. corporation)  
PI US 5837817 981117  
AI US 96-588604 960118 (8)  
RLI Continuation-in-part of Ser. No. US  
94-272005, filed on 7 Jul  
1994, now abandoned  
DT Utility  
LN.CNT 953  
INCL INCLM: 530/350.000  
INCLS: 530/351.000; 435/194.000  
NCL NCLM: 530/350.000

NCLS: 530/351.000; 435/194.000  
IC [6]  
ICM: C07K014-705  
EXF 435/194; 530/350; 530/351

L1 ANSWER 3 OF 405 USPATFULL  
AN 1998:144212 USPATFULL  
TI Interleukin-2 receptor subunit  
ectodomain fusion protein  
comprising a leucine zipper domain  
IN Ciardelli, Thomas L., Sharon, VT,  
United States  
Johnson, Kirk, Moraga, CA, United  
States  
PA Chiron Corporation, Emeryville, CA,  
United States (U.S.  
corporation)  
Trustee of Dartmouth College, Hanover,  
NH, United States (U.S.  
corporation)  
PI US 5837816 981117  
AI US 95-474741 950607 (8)  
RLI Continuation-in-part of Ser. No. US  
95-438259, filed on 10 May  
1995, now abandoned  
DT Utility  
LN.CNT 1970  
INCL INCLM: 530/350.000  
INCLS: 435/069.100; 435/320.100;  
536/023.400; 536/024.100;  
514/002.000  
NCL NCLM: 530/350.000  
NCLS: 435/069.100; 435/320.100;  
536/023.400; 536/024.100;  
514/002.000  
IC [6]  
ICM: C07K014-435  
ICS: C07K014-705; C07K014-715;  
C12N015-12  
EXF 530/350; 435/69.1; 435/320.1;  
435/240.2; 435/325; 435/7.1;  
536/23.4; 514/2  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 4 OF 405 USPATFULL  
AN 1998:144102 USPATFULL  
TI Amino-alcohol substituted cyclic  
compounds  
IN Kumar, Anil M., Seattle, WA, United  
States  
Michnick, John, Seattle, WA, United  
States  
Underiner, Gail E., Brier, WA, United  
States  
Klein, J. Peter, Vashon Island, WA,  
United States  
Rice, Glenn C., Seattle, WA, United  
States  
PA Cell Therapeutics, Inc., Seattle, WA,  
United States (U.S.  
corporation)  
PI US 5837703 981117  
AI US 93-152650 931112 (8)  
RLI Continuation-in-part of Ser. No. US  
93-40820, filed on 31 Mar  
1993, now abandoned  
DT Utility  
LN.CNT 2596  
INCL INCLM: 514/183.000  
INCLS: 514/211.000; 514/228.800;  
514/241.000; 514/242.000;  
514/249.000; 514/256.000;  
514/259.000; 514/263.000;  
514/270.000; 514/274.000;  
514/309.000; 514/312.000;

514/315.000; 514/348.000;  
 514/357.000; 514/374.000;  
 514/400.000; 514/425.000;  
 514/427.000; 540/467.000;  
 540/544.000; 544/216.000;  
 544/257.000; 544/272.000;  
 544/286.000; 544/301.000;  
 544/311.000; 544/335.000;  
 546/096.000; 546/141.000;  
 546/142.000; 546/157.000;  
 546/246.000; 546/296.000;  
 546/334.000; 548/215.000;  
 548/340.100; 548/485.000;  
 548/546.000; 548/561.000  
 NCL NCLM: 514/183.000  
 NCLS: 514/211.000; 514/228.800;  
 514/241.000; 514/242.000;  
 514/249.000; 514/256.000;  
 514/259.000; 514/263.000;  
 514/270.000; 514/274.000;  
 514/309.000; 514/312.000;  
 514/315.000; 514/348.000;  
 514/357.000; 514/374.000;  
 514/400.000; 514/425.000;  
 514/427.000; 540/467.000;  
 540/544.000; 544/216.000;  
 544/257.000; 544/272.000;  
 544/286.000; 544/301.000;  
 544/311.000; 544/335.000;  
 546/096.000; 546/141.000;  
 546/142.000; 546/157.000;  
 546/246.000; 546/296.000;  
 546/334.000; 548/215.000;  
 548/340.100; 548/485.000;  
 548/546.000; 548/561.000  
 IC [6]  
 ICM: A61K031-55  
 ICS: A61K031-515; A61K031-445;  
 A61K031-52  
 EXF 544/276; 544/272; 544/216; 544/257;  
 544/285; 544/286; 544/301;  
 544/311; 544/335; 514/263; 514/183;  
 514/211; 514/228.8; 514/241;  
 514/242; 514/249; 514/256; 514/259;  
 514/270; 514/274; 514/309;  
 514/312; 514/315; 514/348; 514/357;  
 514/374; 514/400; 514/418;  
 514/425; 514/427; 540/467; 540/544;  
 546/96; 546/141; 546/142;  
 546/157; 546/246; 546/296; 546/334;  
 548/215; 548/340.1; 548/485;  
 548/546; 548/561  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 5 OF 405 USPATFULL  
 AN 1998:143939 USPATFULL  
 TI Expression of human multidrug  
 resistance genes and improved  
 selection of cells transduced with  
 such genes  
 IN McDonagh, Kevin T., Silver Spring, MD,  
 United States  
 Nienhuis, Arthur, Bethesda, MD, United  
 States  
 Tolstoshev, Paul, Potomac, MD, United  
 States  
 PA Genetic Therapy, Inc., Gaithersburg,  
 MD, United States (U.S.  
 corporation)  
 The United States of America as  
 represented by the Department of  
 Health and Human Services, Washington,  
 DC, United States (U.S.  
 government)  
 PI US 5837536 981117

AI US 96-583276 960105 (8)  
 RLI Continuation of Ser. No. US 94-332444,  
 filed on 31 Oct 1994, now  
 abandoned which is a continuation of  
 Ser. No. US 92-887712, filed  
 on 22 May 1992, now abandoned  
 DT Utility  
 LN.CNT 1231  
 INCL INCLM: 435/325.000  
 INCLS: 536/023.500; 435/069.100;  
 435/320.100  
 NCL NCLM: 435/325.000  
 NCLS: 536/023.500; 435/069.100;  
 435/320.100  
 IC [6]  
 ICM: C12N005-22  
 ICS: C12N015-12; C12N015-86  
 EXF 536/23.1; 435/69.1; 435/320.1;  
 435/240.2; 435/325

L1 ANSWER 6 OF 405 USPATFULL  
 AN 1998:143904 USPATFULL  
 TI Directed evolution of novel binding  
 proteins  
 IN Ladner, Robert Charles, Ijamsville,  
 MD, United States  
 Gutterman, Sonia Kosow, Belmont, MA,  
 United States  
 Roberts, Bruce Lindsay, Milford, MA,  
 United States  
 Markland, William, Milford, MA, United  
 States  
 Ley, Arthur Charles, Newton, MA,  
 United States  
 Kent, Rachel Baribault, Boxborough,  
 MA, United States  
 PA Dyax, Corp., Cambridge, MA, United  
 States (U.S. corporation)  
 PI US 5837500 981117  
 AI US 95-415922 950403 (8)  
 RLI Continuation of Ser. No. US 93-9319,  
 filed on 26 Jan 1993, now  
 patented, Pat. No. US 5403484 which is  
 a division of Ser. No. US  
 91-664989, filed on 1 Mar 1991, now  
 patented, Pat. No. US 5223409  
 which is a continuation-in-part of  
 Ser. No. US 90-487063, filed on  
 2 Mar 1990, now abandoned which is a  
 continuation-in-part of Ser.  
 No. US 88-240160, filed on 2 Sep 1988,  
 now abandoned  
 DT Utility  
 LN.CNT 15973  
 INCL INCLM: 435/069.700  
 INCLS: 435/172.300; 530/350.000;  
 530/412.000; 536/023.400  
 NCL NCLM: 435/069.700  
 NCLS: 435/172.300; 530/350.000;  
 530/412.000; 536/023.400  
 IC [6]  
 ICM: C12N015-62  
 ICS: C07K019-00  
 EXF 435/69.7; 435/172.3; 530/350; 530/412;  
 536/23.4

L1 ANSWER 7 OF 405 USPATFULL  
 AN 1998:143875 USPATFULL  
 TI Method of recovering a biological  
 molecule from a recombinant  
 microorganism  
 IN Carlson, Peter S., Alexandria, VA,  
 United States  
 Quintero, Ernesto J., McLean, VA,  
 United States

Manyak, David M., Ellicott City, MD,  
United States  
Chmurny, Alan B., Frederick, MD,  
United States  
PA Oceanix Biosciences Corporation,  
Hanover, MD, United States (U.S.  
corporation)  
PI US 5837470 981117  
AI US 98-21984 980211  
RLI Division of Ser. No. US 96-766308,  
filed on 13 Dec 1996  
DT Utility  
LN.CNT 1493  
INCL INCLM: 435/006.000  
INCLS: 435/069.100; 435/172.300;  
435/172.200; 435/252.300  
NCL NCLM: 435/006.000  
NCLS: 435/069.100; 435/172.300;  
435/172.200; 435/252.300  
IC [6]  
ICM: C12Q001-68  
ICS: C12P021-02  
EXF 435/6; 435/69.1; 435/172.2; 435/172.3;  
435/252.3

L1 ANSWER 8 OF 405 USPATFULL  
AN 1998:139020 USPATFULL  
TI Chimeric viral receptor polypeptides  
IN Meruelo, Daniel, Scarborough, NY,  
United States  
Yoshimoto, Takayuki, Tokyo, Japan  
PA New York University, New York, NY,  
United States (U.S.  
corporation)  
PI US 5834589 981110  
AI US 93-132990 931007 (8)  
RLI Continuation-in-part of Ser. No. US  
93-84729, filed on 29 Jun  
1993, now abandoned which is a  
continuation-in-part of Ser. No. US  
92-899075, filed on 11 Jun 1992, now  
abandoned which is a  
continuation-in-part of Ser. No. US  
91-806178, filed on 13 Dec  
1991, now abandoned which is a  
continuation-in-part of Ser. No. US  
90-627950, filed on 14 Dec 1990, now  
abandoned  
DT Utility  
LN.CNT 3800  
INCL INCLM: 530/350.000  
INCLS: 530/387.300; 530/388.300;  
530/389.100; 530/826.000;  
435/171.300  
NCL NCLM: 530/350.000  
NCLS: 530/387.300; 530/388.300;  
530/389.100; 530/826.000;  
435/171.300  
IC [6]  
ICM: C12N015-00  
ICS: C12P021-08; C07K016-00; C07K014-  
00  
EXF 530/350; 530/387.3; 530/387.1;  
530/387.7

L1 ANSWER 9 OF 405 USPATFULL  
AN 1998:138917 USPATFULL  
TI Quinoline sulfonamides and their  
therapeutic use  
IN Dyke, Hazel Joan, Cambridge, United  
Kingdom  
Montana, John Gary, Cambridge, United  
Kingdom  
PA Chiroscience Limited, United Kingdom  
(non-U.S. corporation)

PI US 5834485 981110  
AI US 97-858969 970520 (8)  
PRAI GB 96-10506 960520  
GB 96-23234 961107  
GB 96-26883 961224  
GB 97-8071 970422  
DT Utility  
LN.CNT 732  
INCL INCLM: 514/311.000  
INCLS: 514/312.000; 514/313.000;  
514/314.000; 546/153.000;  
546/155.000; 546/156.000;  
546/157.000; 546/159.000;  
546/160.000; 546/168.000;  
546/169.000; 546/170.000;  
546/172.000  
NCL NCLM: 514/311.000  
NCLS: 514/312.000; 514/313.000;  
514/314.000; 546/153.000;  
546/155.000; 546/156.000;  
546/157.000; 546/159.000;  
546/160.000; 546/168.000;  
546/169.000; 546/170.000;  
546/172.000  
IC [6]  
ICM: C07D215-36  
ICS: A61K031-47  
EXF 546/154; 546/155; 546/156; 546/157;  
546/160; 546/162; 546/172;  
514/311; 514/312; 514/313; 514/314

L1 ANSWER 10 OF 405 USPATFULL  
AN 1998:138868 USPATFULL  
TI Inhibition of TNF-.alpha. pleiotropic  
and cytotoxic effects  
IN Slesarev, Vladimir I., 20 Colebrook  
La., Conroe, TX, United States  
77304  
PI US 5834435 981110  
AI US 96-757477 961127 (8)  
DT Utility  
LN.CNT 611  
INCL INCLM: 514/019.000  
INCLS: 514/008.000; 514/016.000;  
514/921.000; 514/885.000;  
530/322.000  
NCL NCLM: 514/019.000  
NCLS: 514/008.000; 514/016.000;  
514/921.000; 514/885.000;  
530/322.000  
IC [6]  
ICM: A61K038-05  
EXF 514/19; 514/8; 514/16; 514/921;  
514/885; 530/322

L1 ANSWER 11 OF 405 USPATFULL  
AN 1998:138853 USPATFULL  
TI Chemokine binding protein and methods  
of use therefor  
IN McFadden, Grant, Edmonton, Canada  
Lucas, Alexandra, Edmonton, Canada  
PA The John P. Robarts Institute, London,  
Canada (non-U.S.  
corporation)  
PI US 5834419 981110  
AI US 96-634924 960419 (8)  
RLI Continuation-in-part of Ser. No. US  
95-424850, filed on 19 Apr  
1995, now abandoned  
DT Utility  
LN.CNT 1033  
INCL INCLM: 514/002.000  
INCLS: 514/008.000; 514/012.000;  
530/350.000; 424/084.000  
NCL NCLM: 514/002.000

NCLS: 514/008.000; 514/012.000;  
 530/350.000; 424/084.000  
 IC [6]  
 ICM: C61K038-16  
 ICS: C07K014-065  
 EXF 530/350; 514/2; 514/8; 514/12; 424/84

L1 ANSWER 12 OF 405 USPATFULL  
 AN 1998:138709 USPATFULL  
 TI Regulated apoptosis  
 IN Crabtree, Gerald R., Woodside, CA,  
 United States  
 Schreiber, Stuart L., Cambridge, MA,  
 United States  
 Spencer, David M., Los Altos, CA,  
 United States  
 Wandless, Thomas J., Cambridge, MA,  
 United States  
 Belshaw, Peter, Somerville, MA, United  
 States  
 PA President & Fellows of Harvard  
 College, Cambridge, MA, United  
 States (U.S. corporation)  
 Board of Trustees of Leland Stanford  
 Jr. University, Stanford, CA,  
 United States (U.S. corporation)  
 PI US 5834266 981110  
 AI US 94-292597 940818 (8)  
 RLI Continuation-in-part of Ser. No. US  
 94-179143, filed on 7 Jan  
 1994, now abandoned And Ser. No. US  
 94-179748, filed on 7 Jan 1994  
 which is a continuation-in-part of  
 Ser. No. US 93-92977, filed on  
 16 Jul 1993, now abandoned which is a  
 continuation-in-part of Ser.  
 No. US 93-17931, filed on 12 Feb 1993,  
 now abandoned, said Ser.  
 No. US -179143 which is a  
 continuation-in-part of Ser. No. US  
 93-93499, filed on 16 Jul 1993  
 DT Utility  
 LN.CNT 5242  
 INCL INCLM: 435/172.300  
 INCLS: 435/320.100; 435/325.000;  
 435/366.000; 536/234.000  
 NCL NCLM: 435/172.300  
 NCLS: 435/320.100; 435/325.000;  
 435/366.000; 536/234.000  
 IC [6]  
 ICM: C12N015-62  
 ICS: C12N015-63; C12N015-79; C12N005-  
 10  
 EXF 424/93.21; 514/44; 435/69.7;  
 435/240.2; 435/320.1; 435/23.4;  
 435/23.5; 435/325; 435/366; 435/372.3;  
 435/172.3; 536/23.4;  
 536/23.5  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 13 OF 405 USPATFULL  
 AN 1998:138693 USPATFULL  
 TI Method for identifying active domains  
 and amino acid residues in  
 polypeptides and hormone variants  
 IN Wells, James A., Burlingame, CA,  
 United States  
 Cunningham, Brian C., Piedmont, CA,  
 United States  
 PA Genentech, Inc., South San Francisco,  
 CA, United States (U.S.  
 corporation)  
 PI US 5834250 981110  
 AI US 97-903398 970630 (8)

RLI Continuation of Ser. No. US 95-483039,  
 filed on 6 Jun 1995, now  
 patented, Pat. No. US 5766854 which is  
 a continuation of Ser. No.  
 US 94-190723, filed on 2 Feb 1994, now  
 patented, Pat. No. US  
 5580723 which is a continuation of  
 Ser. No. US 92-960227, filed on  
 13 Oct 1992, now abandoned which is a  
 continuation of Ser. No. US  
 92-875204, filed on 27 Apr 1992, now  
 abandoned which is a  
 continuation of Ser. No. US 89-428066,  
 filed on 26 Oct 1989, now  
 abandoned which is a continuation-in-  
 part of Ser. No. US  
 88-264611, filed on 28 Oct 1988, now  
 abandoned  
 DT Utility  
 LN.CNT 3240  
 INCL INCLM: 435/007.100  
 INCLS: 435/004.000; 435/006.000;  
 436/501.000; 530/300.000;  
 530/326.000  
 NCL NCLM: 435/007.100  
 NCLS: 435/004.000; 435/006.000;  
 436/501.000; 530/300.000;  
 530/326.000  
 IC [6]  
 ICM: G01N033-53  
 ICS: G01N033-566  
 EXF 435/7.1; 435/4; 435/6; 435/69.1;  
 435/71.1; 436/501; 530/300;  
 530/326; 530/350; 530/387.1;  
 530/388.1; 530/399; 530/806; 530/808

L1 ANSWER 14 OF 405 USPATFULL  
 AN 1998:138593 USPATFULL  
 TI Composition of photoconductive layer  
 for a color display panel  
 IN Kim, Min Ho, Suwon-si, Korea, Republic  
 of  
 Park, Wan Woo, Suwon-si, Korea,  
 Republic of  
 PA Samsung Display Devices Co., Ltd.,  
 Suwon-si, Korea, Republic of  
 (non-U.S. corporation)  
 PI US 5834144 981110  
 AI US 97-935443 970923 (8)  
 PRAI KR 96-61603 961204  
 KR 96-61606 961204  
 DT Utility  
 LN.CNT 378  
 INCL INCLM: 430/028.000  
 NCL NCLM: 430/028.000  
 IC [6]  
 ICM: G03C005-00  
 EXF 430/28; 430/58; 430/59

L1 ANSWER 15 OF 405 USPATFULL  
 AN 1998:135173 USPATFULL  
 TI Interleukin-8 anti-peptide antibodies  
 IN Schraufstatter, Ingrid U., San Diego,  
 CA, United States  
 Cochran, Charles G., La Jolla, CA,  
 United States  
 PA The Scripps Research Institute, La  
 Jolla, CA, United States (U.S.  
 corporation)  
 PI US 5831032 981103  
 AI US 96-643515 960506 (8)  
 RLI Division of Ser. No. US 94-342348,  
 filed on 21 Nov 1994, now  
 abandoned which is a continuation of  
 Ser. No. US 91-755824, filed

on 6 Sep 1991, now abandoned which is  
a continuation-in-part of  
Ser. No. US 90-581673, filed on 12 Sep  
1990, now abandoned

DT Utility

LN.CNT 1372

INCL INCLM: 530/387.900

INCLS: 530/388.100; 530/388.230;

530/389.200; 530/326.000;

530/412.000; 530/413.000

NCL NCLM: 530/387.900

NCLS: 530/388.100; 530/388.230;

530/389.200; 530/326.000;

530/412.000; 530/413.000

IC [6]

ICM: C07K016-24

EXF 560/387.1; 560/388.1; 560/388.25;

560/389.2; 560/387.9; 560/326;

514/412; 514/413

L1 ANSWER 16 OF 405 USPATFULL

AN 1998:135151 USPATFULL

TI Human receptor for interleukin-12

IN Chua, Anne On, Wayne, NJ, United

States

Gubler, Ulrich Andreas, Glen Ridge,

NJ, United States

PA Hoffmann-La Roche Inc., Nutley, NJ,

United States (U.S.

corporation)

PI US 5831007 981103

AI US 95-419652 950411 (8)

RLI Division of Ser. No. US 94-248532,

filed on 31 May 1994, now

patented, Pat. No. US 5536657 which is

a continuation-in-part of

Ser. No. US 93-94713, filed on 19 Jul

1993, now abandoned

DT Utility

LN.CNT 1929

INCL INCLM: 530/350.000

INCLS: 530/351.000; 514/002.000;

514/008.000

NCL NCLM: 530/350.000

NCLS: 530/351.000; 514/002.000;

514/008.000

IC [6]

ICM: C07K014-715

EXF 514/2; 514/8; 530/350; 530/351

L1 ANSWER 17 OF 405 USPATFULL

AN 1998:135009 USPATEFULL

TI Peptides with bactericidal activity

and endotoxin neutralizing

activity for gram negative bacteria

and methods for their use

IN Gray, Beulah H., St. Paul, MN, United

States

Haseman, Judith R., Eagan, MN, United

States

Mayo, Kevin H., Minnetonka, MN, United

States

PA Regents of the University of

Minnesota, Minneapolis, MN, United

States (U.S. corporation)

PI US 5830860 981103

AI US 96-653632 960524 (8)

RLI Continuation-in-part of Ser. No. US

94-218026, filed on 24 Mar

1994

DT Utility

LN.CNT 3083

INCL INCLM: 514/012.000

INCLS: 514/013.000; 514/014.000;

514/015.000; 514/021.000;

435/069.700

NCL NCLM: 514/012.000

NCLS: 514/013.000; 514/014.000;

514/015.000; 514/021.000;

435/069.700

IC [6]

ICM: A61K038-08

ICS: A61K038-10; A61K038-17

EXF 514/12; 514/13; 514/14; 514/15;

514/21; 435/69.7

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 18 OF 405 USPATFULL

AN 1998:134631 USPATFULL

TI Fas antagonists and uses thereof

IN Lynch, David H., Bainbridge Island,

WA, United States

Alderson, Mark R., Bainbridge Island,

WA, United States

PA Immunex Corporation, Seattle, WA,

United States (U.S. corporation)

PI US 5830469 981103

AI US 95-429499 950426 (8)

RLI Continuation-in-part of Ser. No. US

94-322805, filed on 13 Oct

1994, now patented, Pat. No. US

5620889 which is a

continuation-in-part of Ser. No. US

93-159003, filed on 29 Nov

1993, now abandoned which is a

continuation-in-part of Ser. No. US

93-136817, filed on 14 Oct 1993, now

abandoned

DT Utility

LN.CNT 1993

INCL INCLM: 424/144.100

INCLS: 424/143.100; 424/153.100;

424/154.100; 424/155.100;

424/156.100; 530/388.200;

530/388.220; 530/388.230;

530/388.240; 435/332.000

NCL NCLM: 424/144.100

NCLS: 424/143.100; 424/153.100;

424/154.100; 424/155.100;

424/156.100; 530/388.200;

530/388.220; 530/388.230;

530/388.240; 435/332.000

IC [6]

ICM: A16K039-395

ICS: A16K035-12; C07K016-18; C12N005-

12

EXF 424/141.1; 424/154.1; 424/143.1;

424/140.1; 424/144.1; 424/155.1;

424/156.1; 424/153.1; 530/388.1;

530/387.1; 530/388.73;

530/388.75; 530/388.2; 530/388.22;

530/388.23; 530/388.24; 435/332

L1 ANSWER 19 OF 405 USPATFULL

AN 1998:134626 USPATFULL

TI Regulated transcription of targeted

genes and other biological

events

IN Crabtree, Gerald R., Woodside, CA,

United States

Schreiber, Stuart L., Cambridge, MA,

United States

Spencer, David M., Los Altos, CA,

United States

Wandless, Thomas J., Cambridge, MA,

United States

Belshaw, Peter, Cambridge, MA, United

States

PA President & Fellows of Harvard

College, Cambridge, MA, United

States (U.S. corporation)  
Board of Trustees of Leland S.  
Stanford, Jr. University, Stanford,  
CA, United States (U.S. corporation)  
PI US 5830462 981103  
AI US 95-478386 950607 (8)  
RLI Division of Ser. No. US 95-388653,  
filed on 14 Feb 1995 And a  
continuation-in-part of Ser. No. US  
94-292597, filed on 18 Aug  
1994 which is a continuation-in-part  
of Ser. No. US 94-179748,  
filed on 7 Jan 1994, now abandoned  
which is a continuation-in-part  
of Ser. No. US 93-92977, filed on 16  
Jul 1993, now abandoned which  
is a continuation-in-part of Ser. No.  
US 93-17931, filed on 12 Feb  
1993, now abandoned, said Ser. No. US  
-388653 which is a  
continuation-in-part of Ser. No. US  
94-196043, filed on 11 Feb  
1994 which is a continuation-in-part  
of Ser. No. US -179748  
which is a continuation-in-part of  
Ser. No. US -92977 which is a  
continuation-in-part of Ser. No. US  
-17931  
DT Utility  
LN.CNT 4524  
INCL INCLM: 424/093.210  
INCLS: 435/172.300; 514/044.000  
NCL NCLM: 424/093.210  
NCLS: 435/172.300; 514/044.000  
IC [6]  
ICM: C12N015-63  
ICS: A61K031-70; A61K048-00  
EXF 435/69.1; 435/69.7; 435/240.2;  
435/320.1; 435/172.3; 935/34;  
935/36; 935/70; 935/71; 424/93.21;  
514/44  
L1 ANSWER 20 OF 405 USPATFULL  
AN 1998:134612 USPATFULL  
TI Compositions and methods for the  
treatment of tumors  
IN Vehar, Gordon A., San Carlos, CA,  
United States  
PA Genentech, Inc., South San Francisco,  
CA, United States (U.S.  
corporation)  
PI US 5830448 981103  
AI US 95-470777 950606 (8)  
RLI Division of Ser. No. US 94-260850,  
filed on 16 Jun 1994  
DT Utility  
LN.CNT 1698  
INCL INCLM: 424/085.200  
INCLS: 514/002.000; 530/351.000;  
530/381.000; 424/085.500;  
424/085.100  
NCL NCLM: 424/085.200  
NCLS: 514/002.000; 530/351.000;  
530/381.000; 424/085.500;  
424/085.100  
IC [6]  
ICM: A61K045-05  
ICS: A61K038-00  
EXF 514/2; 530/351; 530/381; 424/85.2;  
424/85.5; 424/85.1  
=> s 11 and (clon? or cdna?)

23616 CLON?  
10407 CDNA?

L2 292 L1 AND (CLON? OR CDNA?)  
=> d 1-20  
L2 ANSWER 1 OF 292 USPATFULL  
AN 1998:144233 USPATFULL  
TI Nucleic acids molecules encoding  
Caspase-8h and Caspase-8i  
IN Hunter, John J., Cambridge, MA, United  
States  
Shyjan, Andrew W., Nahant, MA, United  
States  
Wong, Grace H. W., Brookline, MA,  
United States  
PA Millennium Pharmaceuticals, Inc.,  
Cambridge, MA, United States  
(U.S. corporation)  
PI US 5837837 981117  
AI US 97-807200 970227 (8)  
DT Utility  
LN.CNT 2079  
INCL INCLM: 536/023.100  
INCLS: 530/300.000; 530/350.000  
NCL NCLM: 536/023.100  
NCLS: 530/300.000; 530/350.000  
IC [6]  
ICM: C07H021-02  
ICS: A61K038-00; C07K001-00  
EXF 536/23.1; 530/350; 435/172.3;  
435/69.1; 435/325; 424/93.2  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
L2 ANSWER 2 OF 292 USPATFULL  
AN 1998:144213 USPATFULL  
TI **Tumor necrosis factor**  
**receptor-II-associated protein kinase**  
and methods for its  
use  
IN Aggarwal, Bharat B., Houston, TX,  
United States  
Darnay, Bryant G., Houston, TX, United  
States  
PA Research Development Foundation,  
Carson City, NV, United States  
(U.S. corporation)  
PI US 5837817 981117  
AI US 96-588604 960118 (8)  
RLI Continuation-in-part of Ser. No. US  
94-272005, filed on 7 Jul  
1994, now abandoned  
DT Utility  
LN.CNT 953  
INCL INCLM: 530/350.000  
INCLS: 530/351.000; 435/194.000  
NCL NCLM: 530/350.000  
NCLS: 530/351.000; 435/194.000  
IC [6]  
ICM: C07K014-705  
EXF 435/194; 530/350; 530/351  
L2 ANSWER 3 OF 292 USPATFULL  
AN 1998:144212 USPATFULL  
TI Interleukin-2 receptor subunit  
ectodomain fusion protein  
comprising a leucine zipper domain  
IN Ciardelli, Thomas L., Sharon, VT,  
United States  
Johnson, Kirk, Moraga, CA, United  
States  
PA Chiron Corporation, Emeryville, CA,  
United States (U.S.  
corporation)

Trustee of Dartmouth College, Hanover,  
NH, United States (U.S.  
corporation)

PI US 5837816 981117.  
AI US 95-474741 950607 (8)  
RLI Continuation-in-part of Ser. No. US  
95-438259, filed on 10 May  
1995, now abandoned

DT Utility

LN.CNT 1970

INCL INCLM: 530/350.000

INCLS: 435/069.100; 435/320.100;

536/023.400; 536/024.100;

514/002.000

NCL NCLM: 530/350.000

NCLS: 435/069.100; 435/320.100;

536/023.400; 536/024.100;

514/002.000

IC [6]

ICM: C07K014-435

ICS: C07K014-705; C07K014-715;

C12N015-12

EXF 530/350; 435/69.1; 435/320.1;

435/240.2; 435/325; 435/7.1;

536/23.4; 514/2

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 4 OF 292 USPATEFULL

AN 1998:144102 USPATEFULL

TI Amino-alcohol substituted cyclic  
compounds

IN Kumar, Anil M., Seattle, WA, United  
States

Michnick, John, Seattle, WA, United  
States

Underiner, Gail E., Brier, WA, United  
States

Klein, J. Peter, Vashon Island, WA,  
United States

Rice, Glenn C., Seattle, WA, United  
States

PA Cell Therapeutics, Inc., Seattle, WA,  
United States (U.S.  
corporation)

PI US 5837703 981117

AI US 93-152650 931112 (8)

RLI Continuation-in-part of Ser. No. US  
93-40820, filed on 31 Mar  
1993, now abandoned

DT Utility

LN.CNT 2596

INCL INCLM: 514/183.000

INCLS: 514/211.000; 514/228.800;

514/241.000; 514/242.000;

514/249.000; 514/256.000;

514/259.000; 514/263.000;

514/270.000; 514/274.000;

514/309.000; 514/312.000;

514/315.000; 514/348.000;

514/357.000; 514/374.000;

514/400.000; 514/425.000;

514/427.000; 540/467.000;

540/544.000; 544/216.000;

544/257.000; 544/272.000;

544/286.000; 544/301.000;

544/311.000; 544/335.000;

546/096.000; 546/141.000;

546/142.000; 546/157.000;

546/246.000; 546/296.000;

546/334.000; 548/215.000;

548/340.100; 548/485.000;

548/546.000; 548/561.000

NCL NCLM: 514/183.000

NCLS: 514/211.000; 514/228.800;

514/241.000; 514/242.000;

514/249.000; 514/256.000;

514/259.000; 514/263.000;

514/270.000; 514/274.000;

514/309.000; 514/312.000;

514/315.000; 514/348.000;

514/357.000; 514/374.000;

514/400.000; 514/425.000;

514/427.000; 540/467.000;

540/544.000; 544/216.000;

544/257.000; 544/272.000;

544/286.000; 544/301.000;

544/311.000; 544/335.000;

546/096.000; 546/141.000;

546/142.000; 546/157.000;

546/246.000; 546/296.000;

546/334.000; 548/215.000;

548/340.100; 548/485.000;

548/546.000; 548/561.000

IC [6]

ICM: A61K031-55

ICS: A61K031-515; A61K031-445;

A61K031-52

EXF 544/276; 544/272; 544/216; 544/257;

544/285; 544/286; 544/301;

544/311; 544/335; 514/263; 514/183;

514/211; 514/228.8; 514/241;

514/242; 514/249; 514/256; 514/259;

514/270; 514/274; 514/309;

514/312; 514/315; 514/348; 514/357;

514/374; 514/400; 514/418;

514/425; 514/427; 540/467; 540/544;

546/96; 546/141; 546/142;

546/157; 546/246; 546/296; 546/334;

548/215; 548/340.1; 548/485;

548/546; 548/561

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 5 OF 292 USPATEFULL

AN 1998:143939 USPATEFULL

TI Expression of human multidrug  
resistance genes and improved

selection of cells transduced with  
such genes

IN McDonagh, Kevin T., Silver Spring, MD,  
United States

Nienhuis, Arthur, Bethesda, MD, United  
States

Tolstoshev, Paul, Potomac, MD, United  
States

PA Genetic Therapy, Inc., Gaithersburg,  
MD, United States (U.S.

corporation)

The United States of America as

represented by the Department of

Health and Human Services, Washington,  
DC, United States (U.S.

government)

PI US 5837536 981117

AI US 96-583276 960105 (8)

RLI Continuation of Ser. No. US 94-332444,  
filed on 31 Oct 1994, now

abandoned which is a continuation of  
Ser. No. US 92-887712, filed

on 22 May 1992, now abandoned

DT Utility

LN.CNT 1231

INCL INCLM: 435/325.000

INCLS: 536/023.500; 435/069.100;

435/320.100

NCL NCLM: 435/325.000

NCLS: 536/023.500; 435/069.100;

435/320.100

IC [6]

ICM: C12N005-22

ICS: C12N015-12; C12N015-86

EXF 536/23.1; 435/69.1; 435/320.1;  
435/240.2; 435/325

L2 ANSWER 6 OF 292 USPATFULL  
AN 1998:143904 USPATFULL  
TI Directed evolution of novel binding  
proteins  
IN Ladner, Robert Charles, Ijamsville,  
MD, United States  
United States  
Gutterman, Sonia Kosow, Belmont, MA,  
United States  
Roberts, Bruce Lindsay, Milford, MA,  
United States  
Markland, William, Milford, MA, United  
States  
Ley, Arthur Charles, Newton, MA,  
United States  
Kent, Rachel Baribault, Boxborough,  
MA, United States  
PA Dyax, Corp., Cambridge, MA, United  
States (U.S. corporation)  
PI US 5837500 981117  
AI US 95-415922 950403 (8)  
RLI Continuation of Ser. No. US 93-9319,  
filed on 26 Jan 1993, now  
patented, Pat. No. US 5403484 which is  
a division of Ser. No. US  
91-664989, filed on 1 Mar 1991, now  
patented, Pat. No. US 5223409  
which is a continuation-in-part of  
Ser. No. US 90-487063, filed on  
2 Mar 1990, now abandoned which is a  
continuation-in-part of Ser.  
No. US 88-240160, filed on 2 Sep 1988,  
now abandoned  
DT Utility  
LN.CNT 15973  
INCL INCLM: 435/069.700  
INCLS: 435/172.300; 530/350.000;  
530/412.000; 536/023.400  
NCL NCLM: 435/069.700  
NCLS: 435/172.300; 530/350.000;  
530/412.000; 536/023.400  
IC [6]  
ICM: C12N015-62  
ICS: C07K019-00  
EXF 435/69.7; 435/172.3; 530/350; 530/412;  
536/23.4

L2 ANSWER 7 OF 292 USPATFULL  
AN 1998:143875 USPATFULL  
TI Method of recovering a biological  
molecule from a recombinant  
microorganism  
IN Carlson, Peter S., Alexandria, VA,  
United States  
Quintero, Ernesto J., McLean, VA,  
United States  
Manyak, David M., Ellicott City, MD,  
United States  
Chmurny, Alan B., Frederick, MD,  
United States  
PA Oceanix Biosciences Corporation,  
Hanover, MD, United States (U.S.  
corporation)  
PI US 5837470 981117  
AI US 98-21984 980211  
RLI Division of Ser. No. US 96-766308,  
filed on 13 Dec 1996  
DT Utility  
LN.CNT 1493  
INCL INCLM: 435/006.000  
INCLS: 435/069.100; 435/172.300;  
435/172.200; 435/252.300  
NCL NCLM: 435/006.000

NCLS: 435/069.100; 435/172.300;  
435/172.200; 435/252.300  
IC [6]

ICM: C12Q001-68  
ICS: C12P021-02  
EXF 435/6; 435/69.1; 435/172.2; 435/172.3;  
435/252.3

L2 ANSWER 8 OF 292 USPATFULL  
AN 1998:139020 USPATFULL  
TI Chimeric viral receptor polypeptides  
IN Meruelo, Daniel, Scarborough, NY,  
United States  
Yoshimoto, Takayuki, Tokyo, Japan  
PA New York University, New York, NY,  
United States (U.S.  
corporation)  
PI US 5834589 981110  
AI US 93-132990 931007 (8)  
RLI Continuation-in-part of Ser. No. US  
93-84729, filed on 29 Jun  
1993, now abandoned which is a  
continuation-in-part of Ser. No. US  
92-899075, filed on 11 Jun 1992, now  
abandoned which is a  
continuation-in-part of Ser. No. US  
91-806178, filed on 13 Dec  
1991, now abandoned which is a  
continuation-in-part of Ser. No. US  
90-627950, filed on 14 Dec 1990, now  
abandoned  
DT Utility  
LN.CNT 3800  
INCL INCLM: 530/350.000  
INCLS: 530/387.300; 530/388.300;  
530/389.100; 530/826.000;  
435/171.300  
NCL NCLM: 530/350.000  
NCLS: 530/387.300; 530/388.300;  
530/389.100; 530/826.000;  
435/171.300  
IC [6]  
ICM: C12N015-00  
ICS: C12P021-08; C07K016-00; C07K014-  
00  
EXF 530/350; 530/387.3; 530/387.1;  
530/387.7

L2 ANSWER 9 OF 292 USPATFULL  
AN 1998:138853 USPATFULL  
TI Chemokine binding protein and methods  
of use therefor  
IN McFadden, Grant, Edmonton, Canada  
Lucas, Alexandra, Edmonton, Canada  
PA The John P. Robarts Institute, London,  
Canada (non-U.S.  
corporation)  
PI US 5834419 981110  
AI US 96-634924 960419 (8)  
RLI Continuation-in-part of Ser. No. US  
95-424850, filed on 19 Apr  
1995, now abandoned  
DT Utility  
LN.CNT 1033  
INCL INCLM: 514/002.000  
INCLS: 514/008.000; 514/012.000;  
530/350.000; 424/084.000  
NCL NCLM: 514/002.000  
NCLS: 514/008.000; 514/012.000;  
530/350.000; 424/084.000  
IC [6]  
ICM: C61K038-16  
ICS: C07K014-065  
EXF 530/350; 514/2; 514/8; 514/12; 424/84



L2 ANSWER 10 OF 292 USPATFULL  
 AN 1998:138709 USPATFULL  
 TI Regulated apoptosis.  
 IN Crabtree, Gerald R., Woodside, CA,  
 United States  
 Schreiber, Stuart L., Cambridge, MA,  
 United States  
 Spencer, David M., Los Altos, CA,  
 United States  
 Wandless, Thomas J., Cambridge, MA,  
 United States  
 Belshaw, Peter, Somerville, MA, United  
 States  
 PA President & Fellows of Harvard  
 College, Cambridge, MA, United  
 States (U.S. corporation)  
 Board of Trustees of Leland Stanford  
 Jr. University, Stanford, CA,  
 United States (U.S. corporation)  
 PI US 5834266 981110  
 AI US 94-292597 940818 (8)  
 RLI Continuation-in-part of Ser. No. US  
 94-179143, filed on 7 Jan  
 1994, now abandoned And Ser. No. US  
 94-179748, filed on 7 Jan 1994  
 which is a continuation-in-part of  
 Ser. No. US 93-92977, filed on  
 16 Jul 1993, now abandoned which is a  
 continuation-in-part of Ser.  
 No. US 93-17931, filed on 12 Feb 1993,  
 now abandoned, said Ser.  
 No. US -179143 which is a  
 continuation-in-part of Ser. No. US  
 93-93499, filed on 16 Jul 1993  
 DT Utility  
 LN.CNT 5242  
 INCL INCLM: 435/172.300  
 INCLS: 435/320.100; 435/325.000;  
 435/366.000; 536/234.000  
 NCL NCLM: 435/172.300  
 NCLS: 435/320.100; 435/325.000;  
 435/366.000; 536/234.000  
 IC [6]  
 ICM: C12N015-62  
 ICS: C12N015-63; C12N015-79; C12N005-  
 10  
 EXF 424/93.21; 514/44; 435/69.7;  
 435/240.2; 435/320.1; 435/23.4;  
 435/23.5; 435/325; 435/366; 435/372.3;  
 435/172.3; 536/23.4;  
 536/23.5  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 11 OF 292 USPATFULL  
 AN 1998:138693 USPATFULL  
 TI Method for identifying active domains  
 and amino acid residues in  
 polypeptides and hormone variants  
 IN Wells, James A., Burlingame, CA,  
 United States  
 Cunningham, Brian C., Piedmont, CA,  
 United States  
 PA Genentech, Inc., South San Francisco,  
 CA, United States (U.S.  
 corporation)  
 PI US 5834250 981110  
 AI US 97-903398 970630 (8)  
 RLI Continuation of Ser. No. US 95-483039,  
 filed on 6 Jun 1995, now  
 patented, Pat. No. US 5766854 which is  
 a continuation of Ser. No.  
 US 94-190723, filed on 2 Feb 1994, now  
 patented, Pat. No. US  
 5580723 which is a continuation of  
 Ser. No. US 92-960227, filed on

13 Oct 1992, now abandoned which is a  
 continuation of Ser. No. US  
 92-875204, filed on 27 Apr 1992, now  
 abandoned which is a  
 continuation of Ser. No. US 89-428066,  
 filed on 26 Oct 1989, now  
 abandoned which is a continuation-in-  
 part of Ser. No. US  
 88-264611, filed on 28 Oct 1988, now  
 abandoned  
 DT Utility  
 LN.CNT 3240  
 INCL INCLM: 435/007.100  
 INCLS: 435/004.000; 435/006.000;  
 436/501.000; 530/300.000;  
 530/326.000  
 NCL NCLM: 435/007.100  
 NCLS: 435/004.000; 435/006.000;  
 436/501.000; 530/300.000;  
 530/326.000  
 IC [6]  
 ICM: G01N033-53  
 ICS: G01N033-566  
 EXF 435/7.1; 435/4; 435/6; 435/69.1;  
 435/71.1; 436/501; 530/300;  
 530/326; 530/350; 530/387.1;  
 530/388.1; 530/399; 530/806; 530/808

L2 ANSWER 12 OF 292 USPATFULL  
 AN 1998:135173 USPATFULL  
 TI Interleukin-8 anti-peptide antibodies  
 IN Schraufstatter, Ingrid U., San Diego,  
 CA, United States  
 Cochrane, Charles G., La Jolla, CA,  
 United States  
 PA The Scripps Research Institute, La  
 Jolla, CA, United States (U.S.  
 corporation)  
 PI US 5831032 981103  
 AI US 96-643515 960506 (8)  
 RLI Division of Ser. No. US 94-342348,  
 filed on 21 Nov 1994, now  
 abandoned which is a continuation of  
 Ser. No. US 91-755824, filed  
 on 6 Sep 1991, now abandoned which is  
 a continuation-in-part of  
 Ser. No. US 90-581673, filed on 12 Sep  
 1990, now abandoned  
 DT Utility  
 LN.CNT 1372  
 INCL INCLM: 530/387.900  
 INCLS: 530/388.100; 530/388.230;  
 530/389.200; 530/326.000;  
 530/412.000; 530/413.000  
 NCL NCLM: 530/387.900  
 NCLS: 530/388.100; 530/388.230;  
 530/389.200; 530/326.000;  
 530/412.000; 530/413.000  
 IC [6]  
 ICM: C07K016-24  
 EXF 560/387.1; 560/388.1; 560/388.25;  
 560/389.2; 560/387.9; 560/326;  
 514/412; 514/413

L2 ANSWER 13 OF 292 USPATFULL  
 AN 1998:135151 USPATFULL  
 TI Human receptor for interleukin-12  
 IN Chua, Anne On, Wayne, NJ, United  
 States  
 Gubler, Ulrich Andreas, Glen Ridge,  
 NJ, United States  
 PA Hoffmann-La Roche Inc., Nutley, NJ,  
 United States (U.S.  
 corporation)  
 PI US 5831007 981103

AI US 95-419652 950411 (8)  
RLI Division of Ser. No. US 94-248532,  
filed on 31 May 1994, now  
patented, Pat. No. US 5536657 which is  
a continuation-in-part of  
Ser. No. US 93-94713, filed on 19 Jul  
1993, now abandoned  
DT Utility  
LN.CNT 1929  
INCL INCLM: 530/350.000  
INCLS: 530/351.000; 514/002.000;  
514/008.000  
NCL NCLM: 530/350.000  
NCLS: 530/351.000; 514/002.000;  
514/008.000  
IC [6]  
ICM: C07K014-715  
EXF 514/2; 514/8; 530/350; 530/351

L2 ANSWER 14 OF 292 USPATFULL  
AN 1998:135009 USPATFULL  
TI Peptides with bactericidal activity  
and endotoxin neutralizing  
activity for gram negative bacteria  
and methods for their use  
IN Gray, Beulah H., St. Paul, MN, United  
States  
Haseman, Judith R., Eagan, MN, United  
States  
Mayo, Kevin H., Minnetonka, MN, United  
States  
PA Regents of the University of  
Minnesota, Minneapolis, MN, United  
States (U.S. corporation)  
PI US 5830860 981103  
AI US 96-653632 960524 (8)  
RLI Continuation-in-part of Ser. No. US  
94-218026, filed on 24 Mar  
1994  
DT Utility  
LN.CNT 3083  
INCL INCLM: 514/012.000  
INCLS: 514/013.000; 514/014.000;  
514/015.000; 514/021.000;  
435/069.700  
NCL NCLM: 514/012.000  
NCLS: 514/013.000; 514/014.000;  
514/015.000; 514/021.000;  
435/069.700  
IC [6]  
ICM: A61K038-08  
ICS: A61K038-10; A61K038-17  
EXF 514/12; 514/13; 514/14; 514/15;  
514/21; 435/69.7  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 15 OF 292 USPATFULL  
AN 1998:134631 USPATFULL  
TI Fas antagonists and uses thereof  
IN Lynch, David H., Bainbridge Island,  
WA, United States  
Alderson, Mark R., Bainbridge Island,  
WA, United States  
PA Immunex Corporation, Seattle, WA,  
United States (U.S. corporation)  
PI US 5830469 981103  
AI US 95-429499 950426 (8)  
RLI Continuation-in-part of Ser. No. US  
94-322805, filed on 13 Oct  
1994, now patented, Pat. No. US  
5620889 which is a  
continuation-in-part of Ser. No. US  
93-159003, filed on 29 Nov  
1993, now abandoned which is a  
continuation-in-part of Ser. No. US

93-136817, filed on 14 Oct 1993, now  
abandoned  
DT Utility  
LN.CNT 1993  
INCL INCLM: 424/144.100  
INCLS: 424/143.100; 424/153.100;  
424/154.100; 424/155.100;  
424/156.100; 530/388.200;  
530/388.220; 530/388.230;  
530/388.240; 435/332.000  
NCL NCLM: 424/144.100  
NCLS: 424/143.100; 424/153.100;  
424/154.100; 424/155.100;  
424/156.100; 530/388.200;  
530/388.220; 530/388.230;  
530/388.240; 435/332.000

IC [6]  
ICM: A16K039-395  
ICS: A16K035-12; C07K016-18; C12N005-  
12  
EXF 424/141.1; 424/154.1; 424/143.1;  
424/140.1; 424/144.1; 424/155.1;  
424/156.1; 424/153.1; 530/388.1;  
530/387.1; 530/388.73;  
530/388.75; 530/388.2; 530/388.22;  
530/388.23; 530/388.24; 435/332

L2 ANSWER 16 OF 292 USPATFULL  
AN 1998:134626 USPATFULL  
TI Regulated transcription of targeted  
genes and other biological  
events  
IN Crabtree, Gerald R., Woodside, CA,  
United States  
Schreiber, Stuart L., Cambridge, MA,  
United States  
Spencer, David M., Los Altos, CA,  
United States  
Wandless, Thomas J., Cambridge, MA,  
United States  
Belshaw, Peter, Cambridge, MA, United  
States  
PA President & Fellows of Harvard  
College, Cambridge, MA, United  
States (U.S. corporation)  
Board of Trustees of Leland S.  
Stanford, Jr. University, Stanford,  
CA, United States (U.S. corporation)  
PI US 5830462 981103  
AI US 95-478386 950607 (8)  
RLI Division of Ser. No. US 95-388653,  
filed on 14 Feb 1995 And a  
continuation-in-part of Ser. No. US  
94-292597, filed on 18 Aug  
1994 which is a continuation-in-part  
of Ser. No. US 94-179748,  
filed on 7 Jan 1994, now abandoned  
which is a continuation-in-part  
of Ser. No. US 93-92977, filed on 16  
Jul 1993, now abandoned which  
is a continuation-in-part of Ser. No.  
US 93-17931, filed on 12 Feb  
1993, now abandoned, said Ser. No. US  
-388653 which is a  
continuation-in-part of Ser. No. US  
94-196043, filed on 11 Feb  
1994 which is a continuation-in-part  
of Ser. No. US -179748  
which is a continuation-in-part of  
Ser. No. US -92977 which is a  
continuation-in-part of Ser. No. US  
-17931  
DT Utility  
LN.CNT 4524  
INCL INCLM: 424/093.210

INCLS: 435/172.300; 514/044.000  
NCL NCLM: 424/093.210  
NCLS: 435/172.300; 514/044.000  
IC [6]  
ICM: C12N015-63  
ICS: A61K031-70; A61K048-00  
EXF 435/69.1; 435/69.7; 435/240.2;  
435/320.1; 435/172.3; 935/34;  
935/36; 935/70; 935/71; 424/93.21;  
514/44  
L2 ANSWER 17 OF 292 USPATFULL  
AN 1998:134612 USPATFULL  
TI Compositions and methods for the  
treatment of tumors  
IN Vehar, Gordon A., San Carlos, CA,  
United States  
PA Genentech, Inc., South San Francisco,  
CA, United States (U.S.  
corporation)  
PI US 5830448 981103  
AI US 95-470777 950606 (8)  
RLI Division of Ser. No. US 94-260850,  
filed on 16 Jun 1994  
DT Utility  
LN.CNT 1698  
INCL INCLM: 424/085.200  
INCLS: 514/002.000; 530/351.000;  
530/381.000; 424/085.500;  
424/085.100  
NCL NCLM: 424/085.200  
NCLS: 514/002.000; 530/351.000;  
530/381.000; 424/085.500;  
424/085.100  
IC [6]  
ICM: A61K045-05  
ICS: A61K038-00  
EXF 514/2; 530/351; 530/381; 424/85.2;  
424/85.5; 424/85.1  
L2 ANSWER 18 OF 292 USPATFULL  
AN 1998:128378 USPATFULL  
TI Human stromelysin-1 promoter  
IN Borden, Paula Ann, Palo Alto, CA,  
United States  
Heller, Renu Anand, Stanford, CA,  
United States  
PA Syntex (U.S.A.) Inc., Palo Alto, CA,  
United States (U.S.  
corporation)  
PI US 5824794 981020  
AI US 94-362706 941223 (8)  
DT Utility  
LN.CNT 812  
INCL INCLM: 536/024.100  
INCLS: 435/172.300; 435/320.100;  
435/325.000; 435/366.000;  
435/252.300; 536/023.500  
NCL NCLM: 536/024.100  
NCLS: 435/252.300; 435/320.100;  
435/325.000; 435/366.000;  
536/023.500  
IC [6]  
ICM: C07H021-04  
ICS: C12N005-16; C12N015-12; C12N015-  
85  
EXF 514/44; 536/23.1; 536/24.1; 536/23.5;  
435/320.1; 435/240.2; 435/6;  
435/252.3; 435/366; 435/172.3;  
435/325; 424/93.21  
L2 ANSWER 19 OF 292 USPATFULL  
AN 1998:128265 USPATFULL  
TI Substituted amino alcohol compounds

IN Klein, J. Peter, Vashon, WA, United  
States  
Underiner, Gail E., Brier, WA, United  
States  
Kumar, Anil M., Seattle, WA, United  
States  
PA Cell Therapeutics, Inc., Seattle, WA,  
United States (U.S.  
corporation)  
PI US 5824677 981020  
AI US 95-474816 950607 (8)  
RLI Division of Ser. No. US 94-303842,  
filed on 8 Sep 1994, now  
patented, Pat. No. US 5641783 which is  
a continuation-in-part of  
Ser. No. US 93-152650, filed on 12 Nov  
1993, now patented, Pat.  
No. US 5801181 And Ser. No. US 93-  
164081, filed on 8 Dec 1993, now  
patented, Pat. No. US 5470878, said  
Ser. No. US -152650 And  
Ser. No. US -164081, each Ser. No.  
US - which is a  
continuation-in-part of Ser. No. US  
93-40820, filed on 31 Mar  
1993, now abandoned  
DT Utility  
LN.CNT 3136  
INCL INCLM: 514/222.500  
INCLS: 514/223.500; 514/224.500;  
514/226.800; 514/227.500;  
514/228.800; 514/229.200;  
514/230.500; 514/230.800;  
514/237.800; 514/248.000;  
514/249.000; 514/255.000;  
514/258.000; 514/274.000;  
514/301.000; 514/303.000;  
514/311.000; 514/351.000;  
514/360.000; 514/361.000;  
514/362.000; 514/363.000;  
514/364.000; 514/365.000;  
514/367.000; 514/372.000;  
514/373.000; 514/374.000;  
514/375.000; 514/376.000;  
514/378.000; 514/379.000;  
514/380.000; 514/387.000;  
514/395.000; 514/415.000;  
514/418.000; 514/424.000;  
514/425.000; 514/433.000;  
514/452.000; 514/432.000;  
514/438.000; 346/113.000;  
346/114.000; 346/164.000;  
346/300.000; 549/014.000;  
549/050.000; 549/075.000;  
549/367.000; 549/368.000;  
544/002.000; 544/003.000;  
544/005.000; 544/008.000;  
544/053.000; 544/063.000;  
544/065.000; 544/066.000;  
544/067.000; 544/090.000;  
544/091.000; 544/127.000;  
544/128.000; 544/162.000;  
544/215.000; 544/219.000;  
544/229.000; 544/235.000;  
544/237.000; 544/255.000;  
544/278.000; 544/311.000;  
544/353.000; 544/385.000;  
548/123.000; 548/125.000;  
548/131.000; 548/134.000;  
548/143.000; 548/146.000;  
548/153.000; 548/174.000;  
548/207.000; 548/214.000;  
548/215.000; 548/217.000;  
548/221.000; 548/228.000;  
548/229.000; 548/237.000;

548/240.000; 548/241.000;  
 548/243.000; 548/247.000;  
 548/267.200; 548/303.700;  
 548/307.100; 548/453.000;  
 548/486.000; 548/543.000;  
 548/546.000  
 NCL NCLM: 514/222.500  
 NCLS: 514/223.500; 514/224.500;  
 514/226.800; 514/227.500;  
 514/228.800; 514/229.200;  
 514/230.500; 514/230.800;  
 514/237.800; 514/248.000;  
 514/249.000; 514/255.000;  
 514/258.000; 514/274.000;  
 514/301.000; 514/303.000;  
 514/311.000; 514/351.000;  
 514/360.000; 514/361.000;  
 514/362.000; 514/363.000;  
 514/364.000; 514/365.000;  
 514/367.000; 514/372.000;  
 514/373.000; 514/374.000;  
 514/375.000; 514/376.000;  
 514/378.000; 514/379.000;  
 514/380.000; 514/387.000;  
 514/395.000; 514/415.000;  
 514/418.000; 514/424.000;  
 514/425.000; 514/432.000;  
 514/433.000; 514/438.000;  
 514/452.000; 544/002.000;  
 544/003.000; 544/005.000;  
 544/008.000; 544/053.000;  
 544/063.000; 544/065.000;  
 544/066.000; 544/067.000;  
 544/090.000; 544/091.000;  
 544/127.000; 544/128.000;  
 544/162.000; 544/215.000;  
 544/219.000; 544/229.000;  
 544/235.000; 544/237.000;  
 544/255.000; 544/278.000;  
 544/311.000; 544/353.000;  
 544/385.000; 546/113.000;  
 546/114.000; 546/164.000;  
 546/300.000; 548/123.000;  
 548/125.000; 548/131.000;  
 548/134.000; 548/143.000;  
 548/146.000; 548/153.000;  
 548/174.000; 548/207.000;  
 548/214.000; 548/215.000;  
 548/217.000; 548/221.000;  
 548/228.000; 548/229.000;  
 548/237.000; 548/240.000;  
 548/241.000; 548/243.000;  
 548/247.000; 548/267.200;  
 548/303.700; 548/307.100;  
 548/453.000; 548/486.000;  
 548/543.000; 548/546.000;  
 549/014.000; 549/050.000;  
 549/075.000; 549/367.000;  
 549/368.000  
 IC [6]  
 ICM: A61K031-385  
 ICS: A61K031-445; A61K031-47; A61K031-  
 505  
 EXF 549/75; 549/50; 549/14; 549/367;  
 549/368; 514/432; 514/438;  
 514/222.5; 514/223.5; 514/224.5;  
 514/226.8; 514/227.5; 514/228.8;  
 514/229.2; 514/230.5; 514/230.8;  
 514/237.8; 514/248; 514/249;  
 514/255; 514/258; 514/274; 514/301;  
 514/303; 514/311; 514/351;  
 514/360; 514/361; 514/362; 514/363;  
 514/364; 514/365; 514/367;  
 514/372; 514/373; 514/374; 514/375;  
 514/376; 514/378; 514/379;

514/380; 514/387; 514/395; 514/415;  
 514/418; 514/424; 514/425;  
 514/433; 514/452; 544/2; 544/3; 544/5;  
 544/8; 544/53; 544/63;  
 544/65; 544/66; 544/67; 544/90;  
 544/91; 544/127; 544/128; 544/162;  
 544/215; 544/219; 544/229; 544/235;  
 544/237; 544/255; 544/278;  
 544/311; 544/353; 544/385; 546/113;  
 546/114; 546/164; 546/300;  
 548/123; 548/125; 548/131; 548/134;  
 548/145; 548/146; 548/153;  
 548/174; 548/207; 548/214; 548/215;  
 548/217; 548/221; 548/228;  
 548/229; 548/237; 548/240; 548/241;  
 548/243; 548/247; 548/267.2;  
 548/303.7; 548/307.1; 548/453;  
 548/486; 548/543; 548/546  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 20 OF 292 USPATFULL  
 AN 1998:128224 USPATFULL  
 TI Antiproliferative protein from  
 Bacillus thuringiensis var.  
 thuringiensis  
 IN Aggarwal, Bharat B., Houston, TX,  
 United States  
 Rodriguez-Padilla, Cristina,  
 Monterrey, Mexico  
 PA Research Development Corporation,  
 Carson City, NV, United States  
 (U.S. corporation)  
 Universidad Autonoma de Nuevo Leon,  
 Nuevo Leon, Mexico (non-U.S.  
 corporation)  
 PI US 5824636 981020  
 AI US 96-743553 961104 (8)  
 RLI Continuation of Ser. No. US 95-454636,  
 filed on 31 May 1995, now  
 abandoned  
 DT Utility  
 LN.CNT 823  
 INCL INCLM: 514/002.000  
 INCLS: 530/350.000  
 NCL NCLM: 514/002.000  
 NCLS: 530/350.000  
 IC [6]  
 ICM: A61K039-07  
 ICS: A61K038-16; C07K014-32  
 530/350; 514/2; 424/93.461  
 EXF  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> e greene john/au

E1	1	GREENE JOEL C/AU
E2	1	GREENE JOHATHAN W/AU
E3	2 -->	GREENE JOHN/AU
E4	3	GREENE JOHN D/AU
E5	1	GREENE JOHN F/AU
E6	1	GREENE JOHN L/AU
E7	4	GREENE JOHN M/AU
E8	2	GREENE JOHN P/AU
E9	1	GREENE JONATHAN/AU
E10	1	GREENE JONATHAN A/AU
E11	11	GREENE JONATHAN W/AU
E12	1	GREENE JOSEPH E/AU

=> s e7 and l1

	4	"GREENE JOHN M"/AU
L3	0	"GREENE JOHN M"/AU AND L1

=> e greene j/au

E1	1	GREENE IRWIN D/AU
----	---	-------------------

E2	1	GREENE IRWIN R/AU
E3	0 -->	GREENE J/AU
E4	1	GREENE J JERROLD/AU
E5	2	GREENE JACK C/AU
E6	1	GREENE JACK E/AU
E7	2	GREENE JACK T/AU
E8	3	GREENE JAMES A/AU
E9	1	GREENE JAMES ALBERT/AU
E10	1	GREENE JAMES B/AU
E11	1	GREENE JAMES D/AU
E12	1	GREENE JAMES E/AU

=> e greene jo/au

E1	1	GREENE JERRY/AU
E2	1	GREENE JIMMY D/AU
E3	0 -->	GREENE JO/AU
E4	1	GREENE JOE A/AU
E5	1	GREENE JOEL C/AU
E6	1	GREENE JOHATHAN W/AU
E7	2	GREENE JOHN/AU
E8	3	GREENE JOHN D/AU
E9	1	GREENE JOHN F/AU
E10	1	GREENE JOHN L/AU
E11	4	GREENE JOHN M/AU
E12	2	GREENE JOHN P/AU

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT  
LOGOFF  
LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS  
SINCE FILE TOTAL

ENTRY	SESSION
FULL ESTIMATED COST	
37.55	37.70

STN INTERNATIONAL LOGOFF AT 00:30:26 ON 23  
NOV 1998